FDA OPDP Sends Warning Letter to CytoDyn Over Promotional Video for Its IND… Thomas Sullivan Mar 11, 2022 0 On February 11, 2022, the United States Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) sent a…
HHS District of Delaware Rules HRSA Exceeded Its Authority in Issuing 340B… Thomas Sullivan Mar 10, 2022 0 We have written several times on the December 2020 letter issued by the United States Department of Health and Human Services…
CMS CMS Announces New Flexibilities to QPP and MIPS Thomas Sullivan Mar 9, 2022 0 In light of the Coronavirus (COVID-19) pandemic, the Centers for Medicare and Medicaid Services (CMS) has been implementing…
Opioids Tribal Nations Reach Multi-Million-Dollar Settlement Over Opioid Claims Thomas Sullivan Mar 8, 2022 0 Earlier this year, a handful of pharmaceutical companies reached a multi-million-dollar settlement with Tribal Nations over opioid…
DOJ DOJ and FTC Aim to Increase Merger Enforcement Thomas Sullivan Mar 7, 2022 0 In January 2022, the Federal Trade Commission (FTC) and the Department of Justice (DOJ) Antitrust Division announced a joint…
Transparency Price Transparency: Making Things Clearer or More Confusing? Thomas Sullivan Mar 4, 2022 0 When the United States Centers for Medicare and Medicaid Services (CMS) enacted its price transparency rule on January 1, 2021,…
GAO GAO Adds HHS to High Risk List of Agencies that Need Transformation Thomas Sullivan Mar 3, 2022 0 Earlier this year, the Government Accountability Office (GAO) issued a report that puts the Department of Health and Human…
CMS CMS Sends Out Warning Notices for Transparency Rule Non-Compliance, But No… Thomas Sullivan Mar 2, 2022 0 On January 1, 2021, the Centers for Medicare and Medicaid Services (CMS) implemented a hospital price transparency regulation that…
CME Continuous Professional Development for Drug Prescribing Associated with… Thomas Sullivan Mar 1, 2022 0 In late January 2022, JAMA Network Open published an original investigation, “Cost-effectiveness and Economic Benefit of…
Real World Evidence Industry Calls for Further Clarity and Flexibility on RWD for Regulatory… Thomas Sullivan Feb 28, 2022 0 In September 2021, the United States Food and Drug Administration (FDA) issued a draft guidance, “Real-Word Data: Assessing…